Alan J. Britten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alan J. Britten has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Arturo Chiti
Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
3 shared publications - John S. Fleming
National Institute of Health Research Biomedical Research Unit in Respiratory Disease , Southampton, United Kingdom
3 shared publications - Allison. J. Craig
Royal Marsden NHSFT, Joint Dept Phys, Sutton, England
2 shared publications Andrew Irwin
2 shared publicationsE J Adam
2 shared publications- Jann Mortensen
Copenhagen University Hospital – Rigshospitalet
2 shared publications
Latest Publications
- Open Access
- 11 July 2024
- Published by Taylor & Francis in Aerosol Science and Technology
- Vol. 58 (11) , 1237-1248
Respiratory aerosol emission from oxygen face masks: Filtering and non-filtering masks measured with a manikin model show potential for reduced emissions
- 11 July 2024
- Published by Taylor & Francis in Aerosol Science and Technology
- Vol. 58 (11) , 1237-1248
Open AccessRespiratory aerosol emission from oxygen face masks: Filtering and non-filtering masks measured with a manikin model show potential for reduced emissions
- Open Access
- 8 December 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (6) , 891-898
Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study
In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20% of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45–60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the γ-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 ± 160 photons/s/cm2/sr and 2.41 ± 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (κ = 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 ± 15 μSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.
- 8 December 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (6) , 891-898
Open AccessIntraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study
In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20% of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45–60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the γ-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 ± 160 photons/s/cm2/sr and 2.41 ± 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (κ = 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 ± 15 μSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.
- 1 March 2014
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 67 (3) , 316-319
Hot or not? The 10% rule in sentinel lymph node biopsy for malignant melanoma revisited
- 1 March 2014
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 67 (3) , 316-319
Hot or not? The 10% rule in sentinel lymph node biopsy for malignant melanoma revisited
- 6 February 2013
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 100 (5) , 654-661
Results of a national training programme in sentinel lymph node biopsy for breast cancer
Background New Start, a structured, validated, multidisciplinary training programme in sentinel lymph node biopsy (SLNB), was established to allow the introduction and rapid transfer of appropriate knowledge and technical skills to ensure safe and competent practice across the UK. Methods Multidisciplinary teams attended a theory/skills laboratory course, following which they performed 30 consecutive SLNBs, either concurrently with their standard axillary staging procedure (training model A) or as stand‐alone SLNB (training model B). SLNB was performed according to a standard protocol using the combined technique of isotope (99mTc‐labelled albumin colloid) and blue dye. An accredited New Start trainer mentored the first five procedures in the participant's hospital, or all 30 if stand‐alone. Validation standards for model A and B were a localization rate of at least 90 per cent. In addition, for model A only, in which a minimum of ten patients were required to be node‐positive, a false‐negative rate (FNR) of 10 per cent or less was required. Results From October 2004 to December 2008, 210 SLNB‐naive surgeons, in 103 centres, performed 6685 SLNB procedures. The overall sentinel lymph node (SLN) localization rate was 98·9 (95 per cent confidence interval 98·6 to 99·1) per cent (6610 of 6685) and the FNR 9·1 (7·9 to 10·5) per cent (160 of 1757). The FNR was related to nodal yield, ranging from 14·8 per cent for one node and declining to 9·7, 6·6, 4·7 and 4·1 per cent for two, three, four and more than four SLNs respectively. No learning curve was identified for localization or FNR. Conclusion The programme successfully trained a wide range of UK breast teams to perform safe SLNB and suggested that a standard injection protocol and structured multidisciplinary training can abolish learning curves.
- 6 February 2013
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 100 (5) , 654-661
Results of a national training programme in sentinel lymph node biopsy for breast cancer
Background New Start, a structured, validated, multidisciplinary training programme in sentinel lymph node biopsy (SLNB), was established to allow the introduction and rapid transfer of appropriate knowledge and technical skills to ensure safe and competent practice across the UK. Methods Multidisciplinary teams attended a theory/skills laboratory course, following which they performed 30 consecutive SLNBs, either concurrently with their standard axillary staging procedure (training model A) or as stand‐alone SLNB (training model B). SLNB was performed according to a standard protocol using the combined technique of isotope (99mTc‐labelled albumin colloid) and blue dye. An accredited New Start trainer mentored the first five procedures in the participant's hospital, or all 30 if stand‐alone. Validation standards for model A and B were a localization rate of at least 90 per cent. In addition, for model A only, in which a minimum of ten patients were required to be node‐positive, a false‐negative rate (FNR) of 10 per cent or less was required. Results From October 2004 to December 2008, 210 SLNB‐naive surgeons, in 103 centres, performed 6685 SLNB procedures. The overall sentinel lymph node (SLN) localization rate was 98·9 (95 per cent confidence interval 98·6 to 99·1) per cent (6610 of 6685) and the FNR 9·1 (7·9 to 10·5) per cent (160 of 1757). The FNR was related to nodal yield, ranging from 14·8 per cent for one node and declining to 9·7, 6·6, 4·7 and 4·1 per cent for two, three, four and more than four SLNs respectively. No learning curve was identified for localization or FNR. Conclusion The programme successfully trained a wide range of UK breast teams to perform safe SLNB and suggested that a standard injection protocol and structured multidisciplinary training can abolish learning curves.
- Open Access
- 30 August 2012
- Published by Springer Nature in British Journal of Cancer
- Vol. 107 (8) , 1310-1316
Overestimation of carboplatin doses is avoided by radionuclide GFR measurement
Background: Patients and methods: Results: Conclusion:
- 30 August 2012
- Published by Springer Nature in British Journal of Cancer
- Vol. 107 (8) , 1310-1316
Open AccessOverestimation of carboplatin doses is avoided by radionuclide GFR measurement
Background: Patients and methods: Results: Conclusion:
- 21 May 2011
- Published by Springer Nature in European Radiology
- Vol. 21 (10) , 2211-2217
Significant differences when using MDRD for GFR estimation compared to radionuclide measured clearance
- 21 May 2011
- Published by Springer Nature in European Radiology
- Vol. 21 (10) , 2211-2217
Significant differences when using MDRD for GFR estimation compared to radionuclide measured clearance
- Open Access
- 14 February 2011
- Published by SAGE Publications in Ultrasound
- Vol. 19 (1) , 3-4
Professor Dariush Khadje Nassiri 8th August 1949–20th October 2010
- 14 February 2011
- Published by SAGE Publications in Ultrasound
- Vol. 19 (1) , 3-4
Open AccessProfessor Dariush Khadje Nassiri 8th August 1949–20th October 2010
- 1 December 2010
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (12) , 1506-1507
Methodological study on repeat single photon computerized tomography white cell scanning to monitor efficacy of treatment in inflammatory bowel disease
- 1 December 2010
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (12) , 1506-1507
Methodological study on repeat single photon computerized tomography white cell scanning to monitor efficacy of treatment in inflammatory bowel disease
- 4 February 2010
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (3) , 662-671
Routine quality control recommendations for nuclear medicine instrumentation
- 4 February 2010
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (3) , 662-671
Routine quality control recommendations for nuclear medicine instrumentation
- Open Access
- 1 October 2009
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (11) , 3190-3210
Joint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma
Involvement of the cervical lymph nodes is the most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and the decision of whether to electively treat patients with clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides a minimally invasive method for determining the disease status of the cervical node basin, without the need for a formal neck dissection. This technique potentially improves the accuracy of histologic nodal staging and avoids overtreating three-quarters of this patient population, minimizing associated morbidity. The technique has been validated for patients with OSCC, and larger-scale studies are in progress to determine its exact role in the management of this patient population. This document is designed to outline the current best practice guidelines for the provision of SNB in patients with early-stage OSCC, and to provide a framework for the currently evolving recommendations for its use. Preparation of this guideline was carried out by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the European Association of Nuclear Medicine (EANM) Oncology Committee and the Sentinel European Node Trial (SENT) Committee.
- 1 October 2009
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (11) , 3190-3210
Open AccessJoint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma
Involvement of the cervical lymph nodes is the most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and the decision of whether to electively treat patients with clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides a minimally invasive method for determining the disease status of the cervical node basin, without the need for a formal neck dissection. This technique potentially improves the accuracy of histologic nodal staging and avoids overtreating three-quarters of this patient population, minimizing associated morbidity. The technique has been validated for patients with OSCC, and larger-scale studies are in progress to determine its exact role in the management of this patient population. This document is designed to outline the current best practice guidelines for the provision of SNB in patients with early-stage OSCC, and to provide a framework for the currently evolving recommendations for its use. Preparation of this guideline was carried out by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the European Association of Nuclear Medicine (EANM) Oncology Committee and the Sentinel European Node Trial (SENT) Committee.